Results 61 to 70 of about 2,579 (176)

Ravulizumab in treatment-naïve patients with atypical hemolytic uremic syndrome: a real-world case series

Drug Target Insights
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a potentially life-threatening condition associated with poor clinical outcomes if not treated adequately.
Livia Maria Sorrentino, Candida Iacuzzo, Raffaella Sciri, Miriam Zacchia, Mariarosaria Iannuzzi, Paola Marotta, Piercarla Vitale, Chiara Taglioni, Floriana Secondulfo, Daniela Palazzetti, Rocco Baccaro   +10 more
doaj   +1 more source

Sequential and Concurrent C5 and Neonatal Fc Receptor Inhibition in Prolonged Myasthenic Crisis due to Advanced Invasive Thymoma‐Associated Myasthenia Gravis: A Case Report and Literature Review

Clinical and Experimental Neuroimmunology, Volume 17, Issue 4, November 2026.
ABSTRACT Thymoma‐associated myasthenia gravis (TAMG) is frequently refractory, particularly when complicated by myasthenic crisis in advanced invasive disease. Complement C5 inhibitors and neonatal Fc receptor (FcRn) inhibitors have expanded the treatment of acetylcholine receptor (AChR) antibody‐positive generalized myasthenia gravis; however, their ...
Yuta Kizuka, Yuriko Nakamura, Kensuke Okada, Yu Okubo, Kaoru Kaseda, Hirofumi Toyama, Keisuke Asakura, Atsuya Takeda, Jin Nakahara, Kei Ishizuchi   +9 more
wiley   +1 more source

COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab

Thrombosis Journal, 2021
Background In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in this subgroup.
Sufana Shikdar, Azra Borogovac, Elabdallah Mohamad, Mohamad Khawandanah   +3 more
doaj   +1 more source

Mapping of C5‐Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition

Immunology, Volume 179, Issue 3, Page 444-456, November 2026.
We identify four distinct C5 inhibitory epitopes, including two novel antibodies that selectively block membrane attack complex (MAC) assembly while preserving C5 cleavage and C5a generation. These findings establish selective MAC inhibition as a new therapeutic strategy for complement‐mediated diseases.
Rebekah Sian Cooke, Kok Yung Lee, Georgina Elizabeth Menzies, Masashi Mizuno, Bryan Paul Morgan, Wioleta Milena Zelek   +5 more
wiley   +1 more source

Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison

, 2021
In the absence of a head-to-head study, we assessed the comparative effectiveness of pegcetacoplan, a targeted C3 complement inhibitor, vs. ravulizumab, a C5 complement inhibitor, among patients with paroxysmal nocturnal hemoglobinuria (PNH) previously ...
Scott B. Baver (11341617), Sujata P. Sarda (7175762), Colin Kunzweiler (7932005), Sangeeta Krishnan (3362015), Nikita Mody-Patel (10940665), Natalia Swartz (9490682), Mei Sheng Duh (7493762), Christopher W. Yee (11383246), Rachel H. Bhak (4785444), Sanjana Sundaresan (11341620)   +9 more
core   +1 more source

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

Annals of Clinical and Translational Neurology
Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy and tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials and subsequent ...
Daiki Tokuyasu, Shigeaki Suzuki, Akiyuki Uzawa, Yuriko Nagane, Masayuki Masuda, Shingo Konno, Tomoya Kubota, Makoto Samukawa, Takamichi Sugimoto, Kei Ishizuchi, Munenori Oyama, Manato Yasuda, Hiroyuki Akamine, Yosuke Onishi, Yasushi Suzuki, Naoki Kawaguchi, Naoya Minami, Takashi Kimura, Masanori P. Takahashi, Hiroyuki Murai, Kimiaki Utsugisawa   +20 more
doaj   +1 more source

B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders

Pharmaceuticals, 2021
The first description of neuromyelitis optica by Eugène Devic and Fernand Gault dates back to the 19th century, but only the discovery of aquaporin-4 autoantibodies in a major subset of affected patients in 2004 led to a fundamentally revised disease ...
Jan Traub, Leila Husseini, Martin S. Weber   +2 more
doaj   +1 more source

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3460-3465, October 2026.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest, Simon E. Koele, Nicole C. A. J. van de Kar, Saskia M. C. Langemeijer, Rob ter Heine   +4 more
wiley   +1 more source

UK Cost-Effectiveness of Pegcetacoplan Compared with Ravulizumab for Treatment of Paroxysmal Nocturnal Haemoglobinuria - Supplementary materials.docx

, 2022
   Supplementary Table 1. Estimated utilities based on the Longworth and McKenzie algorithms     Supplementary Table 2. Key scenario analyses    Supplementary Table 3. Probability of developing adverse events per cycle     Supplementary Table 4.
Jameel Nazir (3831556), Zalmai Hakimi (3831568), Richard J Kelly (13012340), Nuno Pinto de Castro (13012337), Michal Pochopien (6192851), Nikita Patel (229224), Chris Knight (8556909), Piotr Wojciechowski (6576620), Eoin McAughey (13012321), Koo Wilson (5548376), Sujata P. Sarda (7175762), Mondher Toumi (46017), Catherine Wiseman (13012335)   +12 more
core   +1 more source

Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature

Frontiers in Immunology, 2023
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired haematopoietic stem cell disease characterized by complement-mediated intravascular hemolysis, thrombosis, and bone marrow failure. Eculizumab and ravulizumab are anti-C5 monoclonal antibodies
Nicole Galli, Nicole Galli, Loredana Pettine, Mauro Panigada, Laura Daprai, Laura Daprai, Grazia Suriano, Anna Grancini, Anna Grancini, Wilma Barcellini, Bruno Fattizzo, Bruno Fattizzo   +11 more
doaj   +1 more source